| (Values in U.S. Thousands) | Dec, 2024 | Sep, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 |
| Sales | 60,260 | 44,070 | 40,410 | 64,030 | 44,750 |
| Sales Growth | +36.74% | +9.06% | -36.89% | +43.08% | -10.50% |
| Net Income | -53,040 | -59,100 | -69,400 | -208,830 | -277,980 |
| Net Income Growth | +10.25% | +14.84% | +66.77% | +24.88% | -269.31% |
23Andme Holding Co. (ME)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
23andMe Inc. is a consumer genetics and research company. It involved in discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory and cardiovascular diseases, in addition to other therapeutic areas. 23andMe Inc., formerly known as VG Acquisition Corp., is headquartered in Sunnyvale, CA.
Fiscal Year End Date: 12/31